id	sid	tid	token	lemma	pos
admet-348	1	1	manuscript	manuscript	PROPN
admet-348	1	2	doi	doi	PROPN
admet-348	1	3	:	:	PUNCT
admet-348	1	4	10.5599	10.5599	NUM
admet-348	1	5	/	/	SYM
admet-348	1	6	admet.4.3.348	admet.4.3.348	PROPN
admet-348	1	7	182	182	NUM
admet-348	1	8	admet	admet	X
admet-348	1	9	&	&	CCONJ
admet-348	1	10	dmpk	dmpk	PROPN
admet-348	1	11	4(3	4(3	NUM
admet-348	1	12	)	)	PUNCT
admet-348	1	13	(	(	PUNCT
admet-348	1	14	2016	2016	NUM
admet-348	1	15	)	)	PUNCT
admet-348	1	16	182	182	NUM
admet-348	1	17	-	-	SYM
admet-348	1	18	185	185	NUM
admet-348	1	19	;	;	PUNCT
admet-348	1	20	doi	doi	NOUN
admet-348	1	21	:	:	PUNCT
admet-348	1	22	10.5599	10.5599	NUM
admet-348	1	23	/	/	SYM
admet-348	1	24	admet.4.3.348	admet.4.3.348	ADJ
admet-348	1	25	open	open	ADJ
admet-348	1	26	access	access	NOUN
admet-348	1	27	:	:	PUNCT
admet-348	1	28	issn	issn	PROPN
admet-348	1	29	:	:	PUNCT
admet-348	1	30	1848	1848	NUM
admet-348	1	31	-	-	SYM
admet-348	1	32	7718	7718	NUM
admet-348	1	33	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-348	1	34	editorial	editorial	NOUN
admet-348	1	35	adme	adme	NOUN
admet-348	1	36	/	/	SYM
admet-348	1	37	dmpk	dmpk	NOUN
admet-348	1	38	in	in	ADP
admet-348	1	39	the	the	DET
admet-348	1	40	development	development	NOUN
admet-348	1	41	and	and	CCONJ
admet-348	1	42	use	use	NOUN
admet-348	1	43	of	of	ADP
admet-348	1	44	tyrosine	tyrosine	NOUN
admet-348	1	45	and	and	CCONJ
admet-348	1	46	serine	serine	NOUN
admet-348	1	47	-	-	PUNCT
admet-348	1	48	threonine	threonine	ADJ
admet-348	1	49	kinase	kinase	NOUN
admet-348	1	50	inhibitors	inhibitor	NOUN
admet-348	1	51	godefridus	godefridus	VERB
admet-348	1	52	j.	j.	PROPN
admet-348	1	53	peters	peters	PROPN
admet-348	1	54	*	*	PROPN
admet-348	1	55	,	,	PUNCT
admet-348	1	56	kin	kin	PROPN
admet-348	1	57	tam+	tam+	PROPN
admet-348	1	58	editors	editor	NOUN
admet-348	1	59	:	:	PUNCT
admet-348	1	60	admet	admet	PROPN
admet-348	1	61	&	&	CCONJ
admet-348	1	62	dmpk	dmpk	PROPN
admet-348	1	63	*	*	PUNCT
admet-348	1	64	department	department	PROPN
admet-348	1	65	of	of	ADP
admet-348	1	66	medical	medical	ADJ
admet-348	1	67	oncology	oncology	NOUN
admet-348	1	68	,	,	PUNCT
admet-348	1	69	vu	vu	PROPN
admet-348	1	70	university	university	PROPN
admet-348	1	71	medical	medical	ADJ
admet-348	1	72	center	center	NOUN
admet-348	1	73	,	,	PUNCT
admet-348	1	74	amsterdam	amsterdam	PROPN
admet-348	1	75	,	,	PUNCT
admet-348	1	76	the	the	DET
admet-348	1	77	netherlands	netherlands	PROPN
admet-348	1	78	.	.	PUNCT
admet-348	2	1	gj.peters@vumc.nl	gj.peters@vumc.nl	NOUN
admet-348	2	2	.	.	PUNCT
admet-348	3	1	+	+	NUM
admet-348	3	2	faculty	faculty	NOUN
admet-348	3	3	of	of	ADP
admet-348	3	4	health	health	NOUN
admet-348	3	5	sciences	sciences	PROPN
admet-348	3	6	,	,	PUNCT
admet-348	3	7	university	university	NOUN
admet-348	3	8	of	of	ADP
admet-348	3	9	macau	macau	PROPN
admet-348	3	10	,	,	PUNCT
admet-348	3	11	taipa	taipa	PROPN
admet-348	3	12	,	,	PUNCT
admet-348	3	13	macau	macau	PROPN
admet-348	3	14	.	.	PUNCT
admet-348	4	1	kin_tam@umac.mo	kin_tam@umac.mo	PROPN
admet-348	4	2	.	.	PUNCT
admet-348	5	1	since	since	SCONJ
admet-348	5	2	the	the	DET
admet-348	5	3	introduction	introduction	NOUN
admet-348	5	4	of	of	ADP
admet-348	5	5	the	the	DET
admet-348	5	6	tyrosine	tyrosine	NOUN
admet-348	5	7	kinase	kinase	PROPN
admet-348	5	8	inhibitor	inhibitor	PROPN
admet-348	5	9	(	(	PUNCT
admet-348	5	10	tki	tki	NOUN
admet-348	5	11	)	)	PUNCT
admet-348	5	12	imatinib	imatinib	NOUN
admet-348	5	13	,	,	PUNCT
admet-348	5	14	for	for	ADP
admet-348	5	15	treatment	treatment	NOUN
admet-348	5	16	of	of	ADP
admet-348	5	17	chronic	chronic	ADJ
admet-348	5	18	myeloid	myeloid	NOUN
admet-348	5	19	leukemia	leukemia	NOUN
admet-348	5	20	(	(	PUNCT
admet-348	5	21	cml	cml	PROPN
admet-348	5	22	)	)	PUNCT
admet-348	5	23	about	about	ADV
admet-348	5	24	30	30	NUM
admet-348	5	25	new	new	ADJ
admet-348	5	26	related	relate	VERB
admet-348	5	27	compounds	compound	NOUN
admet-348	5	28	have	have	AUX
admet-348	5	29	been	be	AUX
admet-348	5	30	registered	register	VERB
admet-348	5	31	by	by	ADP
admet-348	5	32	the	the	DET
admet-348	5	33	us	us	PROPN
admet-348	5	34	fda	fda	PROPN
admet-348	5	35	,	,	PUNCT
admet-348	5	36	the	the	DET
admet-348	5	37	emea	emea	PROPN
admet-348	5	38	and	and	CCONJ
admet-348	5	39	other	other	ADJ
admet-348	5	40	registration	registration	NOUN
admet-348	5	41	authorities	authority	NOUN
admet-348	5	42	for	for	ADP
admet-348	5	43	various	various	ADJ
admet-348	5	44	types	type	NOUN
admet-348	5	45	of	of	ADP
admet-348	5	46	cancers	cancer	NOUN
admet-348	5	47	,	,	PUNCT
admet-348	5	48	both	both	CCONJ
admet-348	5	49	solid	solid	ADJ
admet-348	5	50	tumors	tumor	NOUN
admet-348	5	51	and	and	CCONJ
admet-348	5	52	hematological	hematological	ADJ
admet-348	5	53	malignancies	malignancy	NOUN
admet-348	5	54	.	.	PUNCT
admet-348	6	1	some	some	DET
admet-348	6	2	drugs	drug	NOUN
admet-348	6	3	have	have	AUX
admet-348	6	4	also	also	ADV
admet-348	6	5	been	be	AUX
admet-348	6	6	registered	register	VERB
admet-348	6	7	for	for	ADP
admet-348	6	8	other	other	ADJ
admet-348	6	9	diseases	disease	NOUN
admet-348	6	10	,	,	PUNCT
admet-348	6	11	such	such	ADJ
admet-348	6	12	as	as	ADP
admet-348	6	13	inflammation	inflammation	NOUN
admet-348	6	14	.	.	PUNCT
admet-348	7	1	these	these	DET
admet-348	7	2	compounds	compound	NOUN
admet-348	7	3	do	do	AUX
admet-348	7	4	not	not	PART
admet-348	7	5	only	only	ADV
admet-348	7	6	target	target	VERB
admet-348	7	7	tyrosine	tyrosine	NOUN
admet-348	7	8	kinases	kinase	NOUN
admet-348	7	9	,	,	PUNCT
admet-348	7	10	but	but	CCONJ
admet-348	7	11	also	also	ADV
admet-348	7	12	serine	serine	ADJ
admet-348	7	13	-	-	PUNCT
admet-348	7	14	threonine	threonine	ADJ
admet-348	7	15	kinases	kinase	NOUN
admet-348	8	1	[	[	X
admet-348	8	2	1	1	NUM
admet-348	8	3	,	,	PUNCT
admet-348	8	4	2	2	NUM
admet-348	8	5	]	]	PUNCT
admet-348	8	6	.	.	PUNCT
admet-348	9	1	in	in	ADP
admet-348	9	2	a	a	DET
admet-348	9	3	recent	recent	ADJ
admet-348	9	4	review	review	NOUN
admet-348	9	5	we	we	PRON
admet-348	9	6	showed	show	VERB
admet-348	9	7	that	that	SCONJ
admet-348	9	8	these	these	DET
admet-348	9	9	compounds	compound	NOUN
admet-348	9	10	show	show	VERB
admet-348	9	11	a	a	DET
admet-348	9	12	large	large	ADJ
admet-348	9	13	variation	variation	NOUN
admet-348	9	14	in	in	ADP
admet-348	9	15	their	their	PRON
admet-348	9	16	physico	physico	NOUN
admet-348	9	17	-	-	PUNCT
admet-348	9	18	chemical	chemical	NOUN
admet-348	9	19	properties	property	NOUN
admet-348	9	20	[	[	X
admet-348	9	21	3	3	NUM
admet-348	9	22	]	]	PUNCT
admet-348	9	23	,	,	PUNCT
admet-348	9	24	which	which	PRON
admet-348	9	25	affect	affect	VERB
admet-348	9	26	their	their	PRON
admet-348	9	27	adme	adme	NOUN
admet-348	9	28	properties	property	NOUN
admet-348	9	29	.	.	PUNCT
admet-348	10	1	in	in	ADP
admet-348	10	2	general	general	ADJ
admet-348	10	3	these	these	DET
admet-348	10	4	small	small	ADJ
admet-348	10	5	compounds	compound	NOUN
admet-348	10	6	(	(	PUNCT
admet-348	10	7	mostly	mostly	ADV
admet-348	10	8	<	<	X
admet-348	10	9	500	500	NUM
admet-348	10	10	kd	kd	NOUN
admet-348	10	11	)	)	PUNCT
admet-348	10	12	are	be	AUX
admet-348	10	13	poorly	poorly	ADV
admet-348	10	14	soluble	soluble	ADJ
admet-348	10	15	,	,	PUNCT
admet-348	10	16	which	which	PRON
admet-348	10	17	may	may	AUX
admet-348	10	18	lead	lead	VERB
admet-348	10	19	to	to	ADP
admet-348	10	20	a	a	DET
admet-348	10	21	solubility	solubility	NOUN
admet-348	10	22	limited	limit	VERB
admet-348	10	23	absorption	absorption	NOUN
admet-348	10	24	,	,	PUNCT
admet-348	10	25	while	while	SCONJ
admet-348	10	26	uptake	uptake	ADJ
admet-348	10	27	through	through	ADP
admet-348	10	28	the	the	DET
admet-348	10	29	gut	gut	NOUN
admet-348	10	30	is	be	AUX
admet-348	10	31	dependent	dependent	ADJ
admet-348	10	32	on	on	ADP
admet-348	10	33	protein	protein	NOUN
admet-348	10	34	binding	bind	VERB
admet-348	10	35	[	[	X
admet-348	10	36	4	4	NUM
admet-348	10	37	]	]	PUNCT
admet-348	10	38	.	.	PUNCT
admet-348	11	1	this	this	PRON
admet-348	11	2	leads	lead	VERB
admet-348	11	3	to	to	ADP
admet-348	11	4	a	a	DET
admet-348	11	5	large	large	ADJ
admet-348	11	6	variability	variability	NOUN
admet-348	11	7	in	in	ADP
admet-348	11	8	pharmacokinetics	pharmacokinetic	NOUN
admet-348	11	9	(	(	PUNCT
admet-348	11	10	pk	pk	NOUN
admet-348	11	11	)	)	PUNCT
admet-348	12	1	[	[	X
admet-348	12	2	5	5	NUM
admet-348	12	3	]	]	PUNCT
admet-348	12	4	.	.	PUNCT
admet-348	13	1	it	it	PRON
admet-348	13	2	appeared	appear	VERB
admet-348	13	3	that	that	SCONJ
admet-348	13	4	all	all	DET
admet-348	13	5	these	these	DET
admet-348	13	6	inhibitors	inhibitor	NOUN
admet-348	13	7	obey	obey	VERB
admet-348	13	8	all	all	DET
admet-348	13	9	common	common	ADJ
admet-348	13	10	parameters	parameter	NOUN
admet-348	13	11	that	that	PRON
admet-348	13	12	dictate	dictate	VERB
admet-348	13	13	the	the	DET
admet-348	13	14	variability	variability	NOUN
admet-348	13	15	of	of	ADP
admet-348	13	16	pk	pk	NOUN
admet-348	13	17	(	(	PUNCT
admet-348	13	18	figure	figure	NOUN
admet-348	13	19	1	1	NUM
admet-348	13	20	)	)	PUNCT
admet-348	13	21	.	.	PUNCT
admet-348	14	1	therefore	therefore	ADV
admet-348	14	2	for	for	ADP
admet-348	14	3	several	several	ADJ
admet-348	14	4	of	of	ADP
admet-348	14	5	these	these	DET
admet-348	14	6	drugs	drug	NOUN
admet-348	14	7	,	,	PUNCT
admet-348	14	8	it	it	PRON
admet-348	14	9	would	would	AUX
admet-348	14	10	be	be	AUX
admet-348	14	11	better	well	ADJ
admet-348	14	12	to	to	PART
admet-348	14	13	give	give	VERB
admet-348	14	14	them	they	PRON
admet-348	14	15	with	with	ADP
admet-348	14	16	food	food	NOUN
admet-348	14	17	;	;	PUNCT
admet-348	14	18	despite	despite	SCONJ
admet-348	14	19	this	this	DET
admet-348	14	20	experience	experience	NOUN
admet-348	14	21	pharmaceutical	pharmaceutical	NOUN
admet-348	14	22	companies	company	NOUN
admet-348	14	23	often	often	ADV
admet-348	14	24	advise	advise	VERB
admet-348	14	25	to	to	PART
admet-348	14	26	give	give	VERB
admet-348	14	27	the	the	DET
admet-348	14	28	drugs	drug	NOUN
admet-348	14	29	without	without	ADP
admet-348	14	30	food	food	NOUN
admet-348	14	31	,	,	PUNCT
admet-348	14	32	leading	lead	VERB
admet-348	14	33	to	to	ADP
admet-348	14	34	an	an	DET
admet-348	14	35	even	even	ADV
admet-348	14	36	worse	bad	ADJ
admet-348	14	37	bioavailability	bioavailability	NOUN
admet-348	14	38	[	[	X
admet-348	14	39	6	6	NUM
admet-348	14	40	]	]	PUNCT
admet-348	14	41	.	.	PUNCT
admet-348	15	1	figure	figure	NOUN
admet-348	15	2	1	1	NUM
admet-348	15	3	.	.	PUNCT
admet-348	16	1	sources	source	NOUN
admet-348	16	2	of	of	ADP
admet-348	16	3	variability	variability	NOUN
admet-348	16	4	in	in	ADP
admet-348	16	5	pharmacokinetics	pharmacokinetic	NOUN
admet-348	16	6	(	(	PUNCT
admet-348	16	7	pk	pk	NOUN
admet-348	16	8	)	)	PUNCT
admet-348	16	9	.	.	PUNCT
admet-348	17	1	cam	cam	PROPN
admet-348	17	2	,	,	PUNCT
admet-348	17	3	complementary	complementary	ADJ
admet-348	17	4	and	and	CCONJ
admet-348	17	5	alternative	alternative	ADJ
admet-348	17	6	medicine	medicine	NOUN
admet-348	17	7	.	.	PUNCT
admet-348	18	1	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-348	18	2	mailto:gj.peters@vumc.nl	mailto:gj.peters@vumc.nl	NUM
admet-348	18	3	mailto:kin_tam@umac.mo	mailto:kin_tam@umac.mo	NOUN
admet-348	18	4	admet	admet	PROPN
admet-348	18	5	&	&	CCONJ
admet-348	18	6	dmpk	dmpk	PROPN
admet-348	18	7	4(3	4(3	NUM
admet-348	18	8	)	)	PUNCT
admet-348	18	9	(	(	PUNCT
admet-348	18	10	2016	2016	NUM
admet-348	18	11	)	)	PUNCT
admet-348	18	12	182	182	NUM
admet-348	18	13	-	-	SYM
admet-348	18	14	185	185	NUM
admet-348	18	15	tki	tki	NOUN
admet-348	18	16	special	special	ADJ
admet-348	18	17	issue	issue	NOUN
admet-348	18	18	editorial	editorial	ADJ
admet-348	18	19	doi	doi	NOUN
admet-348	18	20	:	:	PUNCT
admet-348	18	21	10.5599	10.5599	NUM
admet-348	18	22	/	/	SYM
admet-348	18	23	admet.4.3.348	admet.4.3.348	PROPN
admet-348	18	24	183	183	NUM
admet-348	18	25	protein	protein	NOUN
admet-348	18	26	kinases	kinase	NOUN
admet-348	18	27	play	play	VERB
admet-348	18	28	important	important	ADJ
admet-348	18	29	roles	role	NOUN
admet-348	18	30	in	in	ADP
admet-348	18	31	signal	signal	ADJ
admet-348	18	32	transductions	transduction	NOUN
admet-348	18	33	cascades	cascade	NOUN
admet-348	18	34	that	that	PRON
admet-348	18	35	govern	govern	VERB
admet-348	18	36	many	many	ADJ
admet-348	18	37	cellular	cellular	ADJ
admet-348	18	38	events	event	NOUN
admet-348	18	39	(	(	PUNCT
admet-348	18	40	fig	fig	NOUN
admet-348	18	41	.	.	PUNCT
admet-348	19	1	2	2	NUM
admet-348	19	2	)	)	PUNCT
admet-348	19	3	,	,	PUNCT
admet-348	19	4	including	include	VERB
admet-348	19	5	cellular	cellular	ADJ
admet-348	19	6	stability	stability	NOUN
admet-348	19	7	,	,	PUNCT
admet-348	19	8	selective	selective	ADJ
admet-348	19	9	growth	growth	NOUN
admet-348	19	10	disadvantage	disadvantage	NOUN
admet-348	19	11	or	or	CCONJ
admet-348	19	12	apoptotic	apoptotic	ADJ
admet-348	19	13	cell	cell	NOUN
admet-348	19	14	death	death	NOUN
admet-348	20	1	[	[	X
admet-348	20	2	1	1	NUM
admet-348	20	3	]	]	PUNCT
admet-348	20	4	.	.	PUNCT
admet-348	21	1	these	these	DET
admet-348	21	2	compounds	compound	NOUN
admet-348	21	3	are	be	AUX
admet-348	21	4	often	often	ADV
admet-348	21	5	referred	refer	VERB
admet-348	21	6	to	to	ADP
admet-348	21	7	as	as	ADP
admet-348	21	8	targeted	target	VERB
admet-348	21	9	therapy	therapy	NOUN
admet-348	21	10	,	,	PUNCT
admet-348	21	11	since	since	SCONJ
admet-348	21	12	the	the	DET
admet-348	21	13	drugs	drug	NOUN
admet-348	21	14	are	be	AUX
admet-348	21	15	designed	design	VERB
admet-348	21	16	to	to	PART
admet-348	21	17	inhibit	inhibit	VERB
admet-348	21	18	a	a	DET
admet-348	21	19	specific	specific	ADJ
admet-348	21	20	pathway	pathway	NOUN
admet-348	21	21	in	in	ADP
admet-348	21	22	the	the	DET
admet-348	21	23	cancer	cancer	NOUN
admet-348	21	24	cell	cell	NOUN
admet-348	21	25	,	,	PUNCT
admet-348	21	26	usually	usually	ADV
admet-348	21	27	a	a	DET
admet-348	21	28	pathway	pathway	NOUN
admet-348	21	29	which	which	PRON
admet-348	21	30	is	be	AUX
admet-348	21	31	essential	essential	ADJ
admet-348	21	32	for	for	SCONJ
admet-348	21	33	the	the	DET
admet-348	21	34	cancer	cancer	NOUN
admet-348	21	35	cell	cell	NOUN
admet-348	21	36	to	to	PART
admet-348	21	37	survive	survive	VERB
admet-348	21	38	.	.	PUNCT
admet-348	22	1	this	this	DET
admet-348	22	2	property	property	NOUN
admet-348	22	3	is	be	AUX
admet-348	22	4	often	often	ADV
admet-348	22	5	referred	refer	VERB
admet-348	22	6	to	to	ADP
admet-348	22	7	as	as	ADP
admet-348	22	8	oncogene	oncogene	NOUN
admet-348	22	9	addiction	addiction	NOUN
admet-348	22	10	.	.	PUNCT
admet-348	23	1	examples	example	NOUN
admet-348	23	2	are	be	AUX
admet-348	23	3	the	the	DET
admet-348	23	4	above	above	ADV
admet-348	23	5	-	-	PUNCT
admet-348	23	6	mentioned	mention	VERB
admet-348	23	7	imatinib	imatinib	NOUN
admet-348	23	8	,	,	PUNCT
admet-348	23	9	which	which	PRON
admet-348	23	10	is	be	AUX
admet-348	23	11	targeted	target	VERB
admet-348	23	12	against	against	ADP
admet-348	23	13	the	the	DET
admet-348	23	14	bcr	bcr	PROPN
admet-348	23	15	-	-	PROPN
admet-348	23	16	abl	abl	PROPN
admet-348	23	17	kinase	kinase	NOUN
admet-348	23	18	,	,	PUNCT
admet-348	23	19	which	which	PRON
admet-348	23	20	only	only	ADV
admet-348	23	21	occurs	occur	VERB
admet-348	23	22	in	in	ADP
admet-348	23	23	cml	cml	PROPN
admet-348	23	24	.	.	PUNCT
admet-348	24	1	imatinib	imatinib	NOUN
admet-348	24	2	is	be	AUX
admet-348	24	3	also	also	ADV
admet-348	24	4	targeted	target	VERB
admet-348	24	5	against	against	ADP
admet-348	24	6	c	c	NOUN
admet-348	24	7	-	-	PUNCT
admet-348	24	8	kit	kit	NOUN
admet-348	24	9	,	,	PUNCT
admet-348	24	10	which	which	PRON
admet-348	24	11	is	be	AUX
admet-348	24	12	specifically	specifically	ADV
admet-348	24	13	expressed	express	VERB
admet-348	24	14	in	in	ADP
admet-348	24	15	gastrointestinal	gastrointestinal	ADJ
admet-348	24	16	stromal	stromal	ADJ
admet-348	24	17	tumors	tumor	NOUN
admet-348	24	18	(	(	PUNCT
admet-348	24	19	gist	gist	NOUN
admet-348	24	20	)	)	PUNCT
admet-348	24	21	.	.	PUNCT
admet-348	25	1	another	another	DET
admet-348	25	2	early	early	ADJ
admet-348	25	3	example	example	NOUN
admet-348	25	4	includes	include	VERB
admet-348	25	5	the	the	DET
admet-348	25	6	epidermal	epidermal	ADJ
admet-348	25	7	growth	growth	NOUN
admet-348	25	8	factor	factor	NOUN
admet-348	25	9	receptor	receptor	NOUN
admet-348	25	10	(	(	PUNCT
admet-348	25	11	egfr	egfr	X
admet-348	25	12	)	)	PUNCT
admet-348	25	13	which	which	PRON
admet-348	25	14	is	be	AUX
admet-348	25	15	increased	increase	VERB
admet-348	25	16	in	in	ADP
admet-348	25	17	adenocarcinoma	adenocarcinoma	NOUN
admet-348	25	18	,	,	PUNCT
admet-348	25	19	a	a	DET
admet-348	25	20	subtype	subtype	NOUN
admet-348	25	21	of	of	ADP
admet-348	25	22	non	non	ADJ
admet-348	25	23	-	-	ADJ
admet-348	25	24	small	small	ADJ
admet-348	25	25	lung	lung	NOUN
admet-348	25	26	cancer	cancer	NOUN
admet-348	25	27	(	(	PUNCT
admet-348	25	28	nsclc	nsclc	NOUN
admet-348	25	29	)	)	PUNCT
admet-348	25	30	.	.	PUNCT
admet-348	26	1	adenocarcinomas	adenocarcinoma	NOUN
admet-348	26	2	with	with	ADP
admet-348	26	3	an	an	DET
admet-348	26	4	activating	activating	ADJ
admet-348	26	5	mutation	mutation	NOUN
admet-348	26	6	in	in	ADP
admet-348	26	7	egfr	egfr	NOUN
admet-348	26	8	are	be	AUX
admet-348	26	9	sensitive	sensitive	ADJ
admet-348	26	10	to	to	ADP
admet-348	26	11	erlotinib	erlotinib	NOUN
admet-348	26	12	and	and	CCONJ
admet-348	26	13	gefitinib	gefitinib	NOUN
admet-348	26	14	[	[	X
admet-348	26	15	7	7	NUM
admet-348	26	16	]	]	PUNCT
admet-348	26	17	.	.	PUNCT
admet-348	27	1	another	another	DET
admet-348	27	2	example	example	NOUN
admet-348	27	3	is	be	AUX
admet-348	27	4	the	the	DET
admet-348	27	5	alk	alk	NOUN
admet-348	27	6	-	-	PUNCT
admet-348	27	7	eml	eml	NOUN
admet-348	27	8	translocation	translocation	NOUN
admet-348	27	9	in	in	ADP
admet-348	27	10	adenocarcinoma	adenocarcinoma	NOUN
admet-348	27	11	[	[	X
admet-348	27	12	8	8	NUM
admet-348	27	13	]	]	PUNCT
admet-348	27	14	,	,	PUNCT
admet-348	27	15	against	against	ADP
admet-348	27	16	which	which	PRON
admet-348	27	17	crizotinib	crizotinib	NOUN
admet-348	27	18	is	be	AUX
admet-348	27	19	targeted	target	VERB
admet-348	27	20	.	.	PUNCT
admet-348	28	1	to	to	PART
admet-348	28	2	develop	develop	VERB
admet-348	28	3	selective	selective	ADJ
admet-348	28	4	tkis	tkis	NOUN
admet-348	28	5	for	for	ADP
admet-348	28	6	a	a	DET
admet-348	28	7	particular	particular	ADJ
admet-348	28	8	tumor	tumor	NOUN
admet-348	28	9	a	a	DET
admet-348	28	10	thorough	thorough	ADJ
admet-348	28	11	understanding	understanding	NOUN
admet-348	28	12	of	of	ADP
admet-348	28	13	cellular	cellular	ADJ
admet-348	28	14	signaling	signal	VERB
admet-348	28	15	cascades	cascade	NOUN
admet-348	28	16	is	be	AUX
admet-348	28	17	of	of	ADP
admet-348	28	18	utmost	utmost	ADJ
admet-348	28	19	importance	importance	NOUN
admet-348	28	20	,	,	PUNCT
admet-348	28	21	not	not	PART
admet-348	28	22	only	only	ADV
admet-348	28	23	in	in	ADP
admet-348	28	24	the	the	DET
admet-348	28	25	tumor	tumor	NOUN
admet-348	28	26	but	but	CCONJ
admet-348	28	27	also	also	ADV
admet-348	28	28	in	in	ADP
admet-348	28	29	its	its	PRON
admet-348	28	30	neighboring	neighbor	VERB
admet-348	28	31	stroma	stroma	NOUN
admet-348	28	32	,	,	PUNCT
admet-348	28	33	endothelial	endothelial	ADJ
admet-348	28	34	cells	cell	NOUN
admet-348	28	35	and	and	CCONJ
admet-348	28	36	immune	immune	ADJ
admet-348	28	37	cells	cell	NOUN
admet-348	28	38	such	such	ADJ
admet-348	28	39	as	as	ADP
admet-348	28	40	various	various	ADJ
admet-348	28	41	macrophage	macrophage	ADJ
admet-348	28	42	populations	population	NOUN
admet-348	28	43	.	.	PUNCT
admet-348	29	1	also	also	ADV
admet-348	29	2	,	,	PUNCT
admet-348	29	3	communication	communication	NOUN
admet-348	29	4	between	between	ADP
admet-348	29	5	these	these	DET
admet-348	29	6	cells	cell	NOUN
admet-348	29	7	needs	need	VERB
admet-348	29	8	to	to	PART
admet-348	29	9	be	be	AUX
admet-348	29	10	elucidated	elucidate	VERB
admet-348	29	11	.	.	PUNCT
admet-348	30	1	clearly	clearly	ADV
admet-348	30	2	the	the	DET
admet-348	30	3	research	research	NOUN
admet-348	30	4	and	and	CCONJ
admet-348	30	5	development	development	NOUN
admet-348	30	6	along	along	ADP
admet-348	30	7	this	this	DET
admet-348	30	8	direction	direction	NOUN
admet-348	30	9	will	will	AUX
admet-348	30	10	continue	continue	VERB
admet-348	30	11	in	in	ADP
admet-348	30	12	the	the	DET
admet-348	30	13	coming	come	VERB
admet-348	30	14	decades	decade	NOUN
admet-348	30	15	.	.	PUNCT
admet-348	31	1	figure	figure	NOUN
admet-348	31	2	2	2	NUM
admet-348	31	3	.	.	PUNCT
admet-348	31	4	simplified	simplify	VERB
admet-348	31	5	scheme	scheme	NOUN
admet-348	31	6	of	of	ADP
admet-348	31	7	the	the	DET
admet-348	31	8	action	action	NOUN
admet-348	31	9	of	of	ADP
admet-348	31	10	a	a	DET
admet-348	31	11	receptor	receptor	NOUN
admet-348	31	12	tyrosine	tyrosine	NOUN
admet-348	31	13	kinase	kinase	PROPN
admet-348	31	14	.	.	PUNCT
admet-348	32	1	the	the	DET
admet-348	32	2	receptor	receptor	NOUN
admet-348	32	3	is	be	AUX
admet-348	32	4	stimulated	stimulate	VERB
admet-348	32	5	by	by	ADP
admet-348	32	6	a	a	DET
admet-348	32	7	ligand	ligand	NOUN
admet-348	32	8	,	,	PUNCT
admet-348	32	9	often	often	ADV
admet-348	32	10	leading	lead	VERB
admet-348	32	11	to	to	ADP
admet-348	32	12	a	a	DET
admet-348	32	13	dimerization	dimerization	NOUN
admet-348	32	14	,	,	PUNCT
admet-348	32	15	such	such	ADJ
admet-348	32	16	as	as	ADP
admet-348	32	17	with	with	ADP
admet-348	32	18	egfr	egfr	NOUN
admet-348	32	19	.	.	PUNCT
admet-348	33	1	the	the	DET
admet-348	33	2	intracellular	intracellular	ADJ
admet-348	33	3	tyrosine	tyrosine	NOUN
admet-348	33	4	site	site	NOUN
admet-348	33	5	is	be	AUX
admet-348	33	6	phosphorylated	phosphorylate	VERB
admet-348	33	7	with	with	ADP
admet-348	33	8	atp	atp	PROPN
admet-348	33	9	as	as	ADP
admet-348	33	10	the	the	DET
admet-348	33	11	phosphate	phosphate	ADJ
admet-348	33	12	donor	donor	NOUN
admet-348	33	13	,	,	PUNCT
admet-348	33	14	leading	lead	VERB
admet-348	33	15	a	a	DET
admet-348	33	16	cascade	cascade	NOUN
admet-348	33	17	of	of	ADP
admet-348	33	18	signals	signal	NOUN
admet-348	33	19	due	due	ADP
admet-348	33	20	to	to	ADP
admet-348	33	21	the	the	DET
admet-348	33	22	transfer	transfer	NOUN
admet-348	33	23	of	of	ADP
admet-348	33	24	a	a	DET
admet-348	33	25	signal	signal	NOUN
admet-348	33	26	to	to	ADP
admet-348	33	27	one	one	NUM
admet-348	33	28	or	or	CCONJ
admet-348	33	29	more	more	ADJ
admet-348	33	30	kinases	kinase	NOUN
admet-348	33	31	.	.	PUNCT
admet-348	34	1	finally	finally	ADV
admet-348	34	2	the	the	DET
admet-348	34	3	last	last	ADJ
admet-348	34	4	effector	effector	NOUN
admet-348	34	5	(	(	PUNCT
admet-348	34	6	usually	usually	ADV
admet-348	34	7	a	a	DET
admet-348	34	8	transcription	transcription	NOUN
admet-348	34	9	factor	factor	NOUN
admet-348	34	10	)	)	PUNCT
admet-348	34	11	is	be	AUX
admet-348	34	12	activated	activate	VERB
admet-348	34	13	and	and	CCONJ
admet-348	34	14	passes	pass	VERB
admet-348	34	15	the	the	DET
admet-348	34	16	nuclear	nuclear	ADJ
admet-348	34	17	membrane	membrane	NOUN
admet-348	34	18	,	,	PUNCT
admet-348	34	19	resulting	result	VERB
admet-348	34	20	in	in	ADP
admet-348	34	21	a	a	DET
admet-348	34	22	transcriptional	transcriptional	ADJ
admet-348	34	23	modification	modification	NOUN
admet-348	34	24	.	.	PUNCT
admet-348	35	1	a	a	DET
admet-348	35	2	tyrosine	tyrosine	NOUN
admet-348	35	3	kinase	kinase	PROPN
admet-348	35	4	inhibitor	inhibitor	PROPN
admet-348	35	5	binds	bind	VERB
admet-348	35	6	to	to	ADP
admet-348	35	7	the	the	DET
admet-348	35	8	atp	atp	NOUN
admet-348	35	9	binding	bind	VERB
admet-348	35	10	site	site	NOUN
admet-348	35	11	resulting	result	VERB
admet-348	35	12	in	in	ADP
admet-348	35	13	inhibition	inhibition	NOUN
admet-348	35	14	of	of	ADP
admet-348	35	15	this	this	DET
admet-348	35	16	pathway	pathway	NOUN
admet-348	35	17	.	.	PUNCT
admet-348	36	1	in	in	ADP
admet-348	36	2	the	the	DET
admet-348	36	3	early	early	ADJ
admet-348	36	4	discovery	discovery	NOUN
admet-348	36	5	/	/	SYM
admet-348	36	6	development	development	NOUN
admet-348	36	7	phases	phase	NOUN
admet-348	36	8	of	of	ADP
admet-348	36	9	these	these	DET
admet-348	36	10	compounds	compound	NOUN
admet-348	36	11	,	,	PUNCT
admet-348	36	12	the	the	DET
admet-348	36	13	adme	adme	NOUN
admet-348	36	14	and	and	CCONJ
admet-348	36	15	dmpk	dmpk	NOUN
admet-348	36	16	aspects	aspect	NOUN
admet-348	36	17	were	be	AUX
admet-348	36	18	sometimes	sometimes	ADV
admet-348	36	19	neglected	neglect	VERB
admet-348	36	20	,	,	PUNCT
admet-348	36	21	since	since	SCONJ
admet-348	36	22	the	the	DET
admet-348	36	23	focus	focus	NOUN
admet-348	36	24	was	be	AUX
admet-348	36	25	often	often	ADV
admet-348	36	26	on	on	ADP
admet-348	36	27	potency	potency	NOUN
admet-348	36	28	and	and	CCONJ
admet-348	36	29	selectivity	selectivity	NOUN
admet-348	36	30	against	against	ADP
admet-348	36	31	a	a	DET
admet-348	36	32	particular	particular	ADJ
admet-348	36	33	kinase	kinase	NOUN
admet-348	36	34	target	target	NOUN
admet-348	36	35	of	of	ADP
admet-348	36	36	interest	interest	NOUN
admet-348	36	37	.	.	PUNCT
admet-348	37	1	for	for	SCONJ
admet-348	37	2	the	the	DET
admet-348	37	3	first	first	ADJ
admet-348	37	4	tki	tki	NOUN
admet-348	37	5	to	to	PART
admet-348	37	6	be	be	AUX
admet-348	37	7	registered	register	VERB
admet-348	37	8	,	,	PUNCT
admet-348	37	9	imatinib	imatinib	NOUN
admet-348	37	10	,	,	PUNCT
admet-348	37	11	it	it	PRON
admet-348	37	12	is	be	AUX
admet-348	37	13	now	now	ADV
admet-348	37	14	clear	clear	ADJ
admet-348	37	15	that	that	SCONJ
admet-348	37	16	its	its	PRON
admet-348	37	17	efficacy	efficacy	NOUN
admet-348	37	18	is	be	AUX
admet-348	37	19	dependent	dependent	ADJ
admet-348	37	20	on	on	ADP
admet-348	37	21	its	its	PRON
admet-348	37	22	pharmacokinetics	pharmacokinetic	NOUN
admet-348	37	23	,	,	PUNCT
admet-348	37	24	a	a	DET
admet-348	37	25	certain	certain	ADJ
admet-348	37	26	trough	trough	NOUN
admet-348	37	27	level	level	NOUN
admet-348	37	28	(	(	PUNCT
admet-348	37	29	about	about	ADV
admet-348	37	30	1000	1000	NUM
admet-348	37	31	ng	ng	NOUN
admet-348	37	32	/	/	SYM
admet-348	37	33	ml	ml	PROPN
admet-348	37	34	,	,	PUNCT
admet-348	37	35	about	about	ADV
admet-348	37	36	2	2	NUM
admet-348	37	37	μm	μm	NUM
admet-348	37	38	)	)	PUNCT
admet-348	37	39	is	be	AUX
admet-348	37	40	associated	associate	VERB
admet-348	37	41	with	with	ADP
admet-348	37	42	a	a	DET
admet-348	37	43	better	well	ADJ
admet-348	37	44	response	response	NOUN
admet-348	37	45	,	,	PUNCT
admet-348	37	46	although	although	SCONJ
admet-348	37	47	elevated	elevated	ADJ
admet-348	37	48	trough	trough	NOUN
admet-348	37	49	levels	level	NOUN
admet-348	37	50	(	(	PUNCT
admet-348	37	51	>	>	X
admet-348	37	52	1500	1500	NUM
admet-348	37	53	ng	ng	NOUN
admet-348	37	54	/	/	SYM
admet-348	37	55	ml	ml	PROPN
admet-348	37	56	)	)	PUNCT
admet-348	37	57	are	be	AUX
admet-348	37	58	associated	associate	VERB
admet-348	37	59	with	with	ADP
admet-348	37	60	toxicity	toxicity	NOUN
admet-348	37	61	[	[	X
admet-348	37	62	9	9	NUM
admet-348	37	63	,	,	PUNCT
admet-348	37	64	10	10	NUM
admet-348	37	65	]	]	PUNCT
admet-348	37	66	.	.	PUNCT
admet-348	38	1	also	also	ADV
admet-348	38	2	for	for	ADP
admet-348	38	3	sorafenib	sorafenib	NOUN
admet-348	38	4	,	,	PUNCT
admet-348	38	5	a	a	DET
admet-348	38	6	multikinase	multikinase	NOUN
admet-348	38	7	inhibitor	inhibitor	NOUN
admet-348	38	8	of	of	ADP
admet-348	38	9	the	the	DET
admet-348	38	10	vascular	vascular	ADJ
admet-348	38	11	endothelial	endothelial	ADJ
admet-348	38	12	growth	growth	NOUN
admet-348	38	13	factor	factor	NOUN
admet-348	38	14	receptor	receptor	NOUN
admet-348	38	15	(	(	PUNCT
admet-348	38	16	vegfr	vegfr	NOUN
admet-348	38	17	)	)	PUNCT
admet-348	38	18	and	and	CCONJ
admet-348	38	19	the	the	DET
admet-348	38	20	wildtype	wildtype	NOUN
admet-348	38	21	ras	ras	PROPN
admet-348	38	22	-	-	PROPN
admet-348	38	23	raf	raf	PROPN
admet-348	38	24	pathway	pathway	NOUN
admet-348	38	25	,	,	PUNCT
admet-348	38	26	it	it	PRON
admet-348	38	27	was	be	AUX
admet-348	38	28	shown	show	VERB
admet-348	38	29	that	that	SCONJ
admet-348	38	30	the	the	DET
admet-348	38	31	efficacy	efficacy	NOUN
admet-348	38	32	was	be	AUX
admet-348	38	33	related	relate	VERB
admet-348	38	34	to	to	ADP
admet-348	38	35	its	its	PRON
admet-348	38	36	pharmacokinetics	pharmacokinetic	NOUN
admet-348	38	37	.	.	PUNCT
admet-348	39	1	moreover	moreover	ADV
admet-348	39	2	,	,	PUNCT
admet-348	39	3	some	some	PRON
admet-348	39	4	of	of	ADP
admet-348	39	5	its	its	PRON
admet-348	39	6	metabolites	metabolite	NOUN
admet-348	39	7	are	be	AUX
admet-348	39	8	substrates	substrate	NOUN
admet-348	39	9	for	for	ADP
admet-348	39	10	several	several	ADJ
admet-348	39	11	influx	influx	NOUN
admet-348	39	12	and	and	CCONJ
admet-348	39	13	efflux	efflux	VERB
admet-348	39	14	pumps	pump	NOUN
admet-348	39	15	[	[	X
admet-348	39	16	10	10	NUM
admet-348	39	17	,	,	PUNCT
admet-348	39	18	11	11	NUM
admet-348	39	19	]	]	PUNCT
admet-348	39	20	.	.	PUNCT
admet-348	40	1	these	these	DET
admet-348	40	2	properties	property	NOUN
admet-348	40	3	lead	lead	VERB
admet-348	40	4	to	to	ADP
admet-348	40	5	suboptimal	suboptimal	ADJ
admet-348	40	6	efficacy	efficacy	NOUN
admet-348	40	7	and	and	CCONJ
admet-348	40	8	unexpected	unexpected	ADJ
admet-348	40	9	toxicity	toxicity	NOUN
admet-348	40	10	.	.	PUNCT
admet-348	41	1	for	for	ADP
admet-348	41	2	some	some	DET
admet-348	41	3	drugs	drug	NOUN
admet-348	41	4	this	this	PRON
admet-348	41	5	resulted	result	VERB
admet-348	41	6	in	in	ADP
admet-348	41	7	development	development	NOUN
admet-348	41	8	failures	failure	NOUN
admet-348	41	9	in	in	ADP
admet-348	41	10	the	the	DET
admet-348	41	11	g.	g.	PROPN
admet-348	41	12	peters	peters	PROPN
admet-348	41	13	and	and	CCONJ
admet-348	41	14	k.	k.	PROPN
admet-348	41	15	tam	tam	PROPN
admet-348	41	16	admet	admet	PROPN
admet-348	41	17	&	&	CCONJ
admet-348	41	18	dmpk	dmpk	PROPN
admet-348	41	19	4(3	4(3	NUM
admet-348	41	20	)	)	PUNCT
admet-348	41	21	(	(	PUNCT
admet-348	41	22	2016	2016	NUM
admet-348	41	23	)	)	PUNCT
admet-348	41	24	182	182	NUM
admet-348	41	25	-	-	SYM
admet-348	41	26	185	185	NUM
admet-348	41	27	184	184	NUM
admet-348	41	28	late	late	ADJ
admet-348	41	29	phases	phase	NOUN
admet-348	41	30	.	.	PUNCT
admet-348	42	1	a	a	DET
admet-348	42	2	recent	recent	ADJ
admet-348	42	3	example	example	NOUN
admet-348	42	4	is	be	AUX
admet-348	42	5	the	the	DET
admet-348	42	6	discontinuation	discontinuation	NOUN
admet-348	42	7	of	of	ADP
admet-348	42	8	rociletinib	rociletinib	NOUN
admet-348	42	9	[	[	X
admet-348	42	10	7	7	NUM
admet-348	42	11	]	]	PUNCT
admet-348	42	12	,	,	PUNCT
admet-348	42	13	an	an	DET
admet-348	42	14	inhibitor	inhibitor	NOUN
admet-348	42	15	of	of	ADP
admet-348	42	16	the	the	DET
admet-348	42	17	t790	t790	NUM
admet-348	42	18	m	m	NOUN
admet-348	42	19	mutation	mutation	NOUN
admet-348	42	20	of	of	ADP
admet-348	42	21	efgr	efgr	NOUN
admet-348	42	22	.	.	PUNCT
admet-348	43	1	this	this	DET
admet-348	43	2	t790	t790	NUM
admet-348	43	3	m	m	NOUN
admet-348	43	4	mutation	mutation	NOUN
admet-348	43	5	commonly	commonly	ADV
admet-348	43	6	develops	develop	VERB
admet-348	43	7	after	after	ADP
admet-348	43	8	treatment	treatment	NOUN
admet-348	43	9	with	with	ADP
admet-348	43	10	erlotinib	erlotinib	NOUN
admet-348	43	11	or	or	CCONJ
admet-348	43	12	gefitinib	gefitinib	NOUN
admet-348	43	13	.	.	PUNCT
admet-348	44	1	rociletinib	rociletinib	NOUN
admet-348	44	2	was	be	AUX
admet-348	44	3	granted	grant	VERB
admet-348	44	4	breakthrough	breakthrough	NOUN
admet-348	44	5	therapy	therapy	NOUN
admet-348	44	6	status	status	NOUN
admet-348	44	7	from	from	ADP
admet-348	44	8	the	the	DET
admet-348	44	9	fda	fda	PROPN
admet-348	44	10	for	for	ADP
admet-348	44	11	accelerated	accelerate	VERB
admet-348	44	12	development	development	NOUN
admet-348	44	13	,	,	PUNCT
admet-348	44	14	but	but	CCONJ
admet-348	44	15	in	in	ADP
admet-348	44	16	the	the	DET
admet-348	44	17	phase	phase	NOUN
admet-348	44	18	iii	iii	NUM
admet-348	44	19	trial	trial	NOUN
admet-348	44	20	severe	severe	ADJ
admet-348	44	21	grade	grade	NOUN
admet-348	44	22	3	3	NUM
admet-348	44	23	toxicity	toxicity	NOUN
admet-348	44	24	(	(	PUNCT
admet-348	44	25	hyperglycemia	hyperglycemia	NOUN
admet-348	44	26	)	)	PUNCT
admet-348	44	27	was	be	AUX
admet-348	44	28	observed	observe	VERB
admet-348	44	29	in	in	ADP
admet-348	44	30	22	22	NUM
admet-348	44	31	%	%	NOUN
admet-348	44	32	of	of	ADP
admet-348	44	33	the	the	DET
admet-348	44	34	patients	patient	NOUN
admet-348	44	35	due	due	ADJ
admet-348	44	36	to	to	ADP
admet-348	44	37	inhibition	inhibition	NOUN
admet-348	44	38	of	of	ADP
admet-348	44	39	the	the	DET
admet-348	44	40	insulin	insulin	NOUN
admet-348	44	41	-	-	PUNCT
admet-348	44	42	like	like	ADJ
admet-348	44	43	growth	growth	NOUN
admet-348	44	44	factor	factor	NOUN
admet-348	44	45	receptor	receptor	NOUN
admet-348	44	46	(	(	PUNCT
admet-348	44	47	igfr	igfr	NOUN
admet-348	44	48	)	)	PUNCT
admet-348	44	49	.	.	PUNCT
admet-348	45	1	thirty	thirty	NUM
admet-348	45	2	-	-	PUNCT
admet-348	45	3	five	five	NUM
admet-348	45	4	percent	percent	NOUN
admet-348	45	5	of	of	ADP
admet-348	45	6	the	the	DET
admet-348	45	7	patients	patient	NOUN
admet-348	45	8	had	have	VERB
admet-348	45	9	to	to	PART
admet-348	45	10	take	take	VERB
admet-348	45	11	a	a	DET
admet-348	45	12	glucose	glucose	NOUN
admet-348	45	13	lowering	lower	VERB
admet-348	45	14	drug	drug	NOUN
admet-348	45	15	(	(	PUNCT
admet-348	45	16	usually	usually	ADV
admet-348	45	17	metformin	metformin	NOUN
admet-348	45	18	)	)	PUNCT
admet-348	45	19	.	.	PUNCT
admet-348	46	1	furthermore	furthermore	ADV
admet-348	46	2	some	some	DET
admet-348	46	3	responders	responder	NOUN
admet-348	46	4	could	could	AUX
admet-348	46	5	not	not	PART
admet-348	46	6	be	be	AUX
admet-348	46	7	verified	verify	VERB
admet-348	46	8	at	at	ADP
admet-348	46	9	an	an	DET
admet-348	46	10	independent	independent	ADJ
admet-348	46	11	evaluation	evaluation	NOUN
admet-348	46	12	,	,	PUNCT
admet-348	46	13	with	with	ADP
admet-348	46	14	a	a	DET
admet-348	46	15	drop	drop	NOUN
admet-348	46	16	in	in	ADP
admet-348	46	17	response	response	NOUN
admet-348	46	18	rate	rate	NOUN
admet-348	46	19	from	from	ADP
admet-348	46	20	59	59	NUM
admet-348	46	21	to	to	PART
admet-348	46	22	32	32	NUM
admet-348	46	23	%	%	NOUN
admet-348	46	24	.	.	PUNCT
admet-348	47	1	this	this	DET
admet-348	47	2	compound	compound	NOUN
admet-348	47	3	would	would	AUX
admet-348	47	4	have	have	AUX
admet-348	47	5	benefited	benefit	VERB
admet-348	47	6	from	from	ADP
admet-348	47	7	a	a	DET
admet-348	47	8	more	more	ADV
admet-348	47	9	extensive	extensive	ADJ
admet-348	47	10	evaluation	evaluation	NOUN
admet-348	47	11	.	.	PUNCT
admet-348	48	1	another	another	DET
admet-348	48	2	specific	specific	ADJ
admet-348	48	3	inhibitor	inhibitor	NOUN
admet-348	48	4	of	of	ADP
admet-348	48	5	the	the	DET
admet-348	48	6	t790	t790	NUM
admet-348	48	7	m	m	NOUN
admet-348	48	8	mutation	mutation	NOUN
admet-348	48	9	of	of	ADP
admet-348	48	10	egfr	egfr	NOUN
admet-348	48	11	,	,	PUNCT
admet-348	48	12	osimertinib	osimertinib	NOUN
admet-348	48	13	,	,	PUNCT
admet-348	48	14	did	do	AUX
admet-348	48	15	not	not	PART
admet-348	48	16	suffer	suffer	VERB
admet-348	48	17	from	from	ADP
admet-348	48	18	this	this	DET
admet-348	48	19	problem	problem	NOUN
admet-348	48	20	,	,	PUNCT
admet-348	48	21	and	and	CCONJ
admet-348	48	22	was	be	AUX
admet-348	48	23	recently	recently	ADV
admet-348	48	24	registered	register	VERB
admet-348	48	25	by	by	ADP
admet-348	48	26	the	the	DET
admet-348	48	27	fda	fda	PROPN
admet-348	48	28	after	after	ADP
admet-348	48	29	a	a	DET
admet-348	48	30	similar	similar	ADJ
admet-348	48	31	breakthrough	breakthrough	NOUN
admet-348	48	32	therapy	therapy	NOUN
admet-348	48	33	status	status	NOUN
admet-348	48	34	and	and	CCONJ
admet-348	48	35	an	an	DET
admet-348	48	36	accelerated	accelerated	ADJ
admet-348	48	37	development	development	NOUN
admet-348	48	38	program	program	NOUN
admet-348	48	39	.	.	PUNCT
admet-348	49	1	in	in	ADP
admet-348	49	2	this	this	DET
admet-348	49	3	special	special	ADJ
admet-348	49	4	issue	issue	NOUN
admet-348	49	5	of	of	ADP
admet-348	49	6	admet	admet	NOUN
admet-348	49	7	and	and	CCONJ
admet-348	49	8	dmpk	dmpk	NOUN
admet-348	49	9	we	we	PRON
admet-348	49	10	intended	intend	VERB
admet-348	49	11	to	to	PART
admet-348	49	12	illustrate	illustrate	VERB
admet-348	49	13	a	a	DET
admet-348	49	14	number	number	NOUN
admet-348	49	15	of	of	ADP
admet-348	49	16	issues	issue	NOUN
admet-348	49	17	important	important	ADJ
admet-348	49	18	in	in	ADP
admet-348	49	19	the	the	DET
admet-348	49	20	development	development	NOUN
admet-348	49	21	of	of	ADP
admet-348	49	22	various	various	ADJ
admet-348	49	23	protein	protein	NOUN
admet-348	49	24	kinase	kinase	NOUN
admet-348	49	25	inhibitors	inhibitor	NOUN
admet-348	49	26	,	,	PUNCT
admet-348	49	27	with	with	ADP
admet-348	49	28	a	a	DET
admet-348	49	29	special	special	ADJ
admet-348	49	30	focus	focus	NOUN
admet-348	49	31	on	on	ADP
admet-348	49	32	the	the	DET
admet-348	49	33	admet	admet	NOUN
admet-348	49	34	and	and	CCONJ
admet-348	49	35	dmpk	dmpk	NOUN
admet-348	49	36	aspects	aspect	NOUN
admet-348	49	37	of	of	ADP
admet-348	49	38	these	these	DET
admet-348	49	39	compounds	compound	NOUN
admet-348	49	40	,	,	PUNCT
admet-348	49	41	and	and	CCONJ
admet-348	49	42	how	how	SCONJ
admet-348	49	43	to	to	PART
admet-348	49	44	properly	properly	ADV
admet-348	49	45	incorporate	incorporate	VERB
admet-348	49	46	the	the	DET
admet-348	49	47	basic	basic	ADJ
admet-348	49	48	admet	admet	NOUN
admet-348	49	49	and	and	CCONJ
admet-348	49	50	dmpk	dmpk	NOUN
admet-348	49	51	information	information	NOUN
admet-348	49	52	to	to	PART
admet-348	49	53	optimize	optimize	VERB
admet-348	49	54	the	the	DET
admet-348	49	55	design	design	NOUN
admet-348	49	56	of	of	ADP
admet-348	49	57	clinical	clinical	ADJ
admet-348	49	58	trials	trial	NOUN
admet-348	49	59	.	.	PUNCT
admet-348	50	1	the	the	DET
admet-348	50	2	papers	paper	NOUN
admet-348	50	3	will	will	AUX
admet-348	50	4	be	be	AUX
admet-348	50	5	divided	divide	VERB
admet-348	50	6	between	between	ADP
admet-348	50	7	the	the	DET
admet-348	50	8	september	september	PROPN
admet-348	50	9	and	and	CCONJ
admet-348	50	10	december	december	PROPN
admet-348	50	11	issues	issue	NOUN
admet-348	50	12	.	.	PUNCT
admet-348	51	1	thompson	thompson	NOUN
admet-348	51	2	et	et	PROPN
admet-348	51	3	al	al	PROPN
admet-348	52	1	[	[	X
admet-348	52	2	12	12	NUM
admet-348	52	3	]	]	PUNCT
admet-348	52	4	give	give	VERB
admet-348	52	5	an	an	DET
admet-348	52	6	overview	overview	NOUN
admet-348	52	7	on	on	ADP
admet-348	52	8	the	the	DET
admet-348	52	9	mechanism	mechanism	NOUN
admet-348	52	10	of	of	ADP
admet-348	52	11	action	action	NOUN
admet-348	52	12	of	of	ADP
admet-348	52	13	currently	currently	ADV
admet-348	52	14	used	use	VERB
admet-348	52	15	egfr	egfr	NOUN
admet-348	52	16	and	and	CCONJ
admet-348	52	17	alk	alk	VERB
admet-348	52	18	directed	direct	VERB
admet-348	52	19	compounds	compound	NOUN
admet-348	52	20	,	,	PUNCT
admet-348	52	21	describing	describe	VERB
admet-348	52	22	the	the	DET
admet-348	52	23	issues	issue	NOUN
admet-348	52	24	mentioned	mention	VERB
admet-348	52	25	above	above	ADV
admet-348	52	26	.	.	PUNCT
admet-348	53	1	shah	shah	PROPN
admet-348	53	2	[	[	X
admet-348	53	3	13	13	NUM
admet-348	53	4	]	]	PUNCT
admet-348	53	5	describes	describe	VERB
admet-348	53	6	a	a	DET
admet-348	53	7	less	less	ADV
admet-348	53	8	common	common	ADJ
admet-348	53	9	side	side	NOUN
admet-348	53	10	-	-	PUNCT
admet-348	53	11	effect	effect	NOUN
admet-348	53	12	of	of	ADP
admet-348	53	13	these	these	DET
admet-348	53	14	compounds	compound	NOUN
admet-348	53	15	,	,	PUNCT
admet-348	53	16	cardiovascular	cardiovascular	ADJ
admet-348	53	17	toxicity	toxicity	NOUN
admet-348	53	18	.	.	PUNCT
admet-348	54	1	this	this	DET
admet-348	54	2	type	type	NOUN
admet-348	54	3	of	of	ADP
admet-348	54	4	toxicity	toxicity	NOUN
admet-348	54	5	is	be	AUX
admet-348	54	6	also	also	ADV
admet-348	54	7	quite	quite	ADV
admet-348	54	8	common	common	ADJ
admet-348	54	9	for	for	SCONJ
admet-348	54	10	several	several	ADJ
admet-348	54	11	of	of	ADP
admet-348	54	12	the	the	DET
admet-348	54	13	chemotherapeutic	chemotherapeutic	ADJ
admet-348	54	14	agents	agent	NOUN
admet-348	54	15	and	and	CCONJ
admet-348	54	16	oncologists	oncologist	NOUN
admet-348	54	17	usually	usually	ADV
admet-348	54	18	know	know	VERB
admet-348	54	19	how	how	SCONJ
admet-348	54	20	to	to	PART
admet-348	54	21	deal	deal	VERB
admet-348	54	22	with	with	ADP
admet-348	54	23	these	these	DET
admet-348	54	24	patients	patient	NOUN
admet-348	54	25	.	.	PUNCT
admet-348	55	1	according	accord	VERB
admet-348	55	2	to	to	ADP
admet-348	55	3	shah	shah	NOUN
admet-348	55	4	the	the	DET
admet-348	55	5	hallmark	hallmark	NOUN
admet-348	55	6	of	of	ADP
admet-348	55	7	cardiovascular	cardiovascular	ADJ
admet-348	55	8	function	function	NOUN
admet-348	55	9	,	,	PUNCT
admet-348	55	10	qt	qt	NOUN
admet-348	55	11	aberrations	aberration	NOUN
admet-348	55	12	,	,	PUNCT
admet-348	55	13	are	be	AUX
admet-348	55	14	often	often	ADV
admet-348	55	15	overemphasized	overemphasize	VERB
admet-348	55	16	.	.	PUNCT
admet-348	56	1	this	this	DET
admet-348	56	2	toxicity	toxicity	NOUN
admet-348	56	3	was	be	AUX
admet-348	56	4	also	also	ADV
admet-348	56	5	observed	observe	VERB
admet-348	56	6	for	for	ADP
admet-348	56	7	rociletinib	rociletinib	NOUN
admet-348	56	8	,	,	PUNCT
admet-348	56	9	but	but	CCONJ
admet-348	56	10	not	not	PART
admet-348	56	11	a	a	DET
admet-348	56	12	reason	reason	NOUN
admet-348	56	13	for	for	ADP
admet-348	56	14	its	its	PRON
admet-348	56	15	withdrawal	withdrawal	NOUN
admet-348	56	16	.	.	PUNCT
admet-348	57	1	pott	pott	PROPN
admet-348	57	2	et	et	PROPN
admet-348	57	3	al	al	PROPN
admet-348	58	1	[	[	X
admet-348	58	2	14	14	NUM
admet-348	58	3	]	]	PUNCT
admet-348	58	4	describe	describe	VERB
admet-348	58	5	a	a	DET
admet-348	58	6	cross	cross	NOUN
admet-348	58	7	-	-	NOUN
admet-348	58	8	talk	talk	NOUN
admet-348	58	9	between	between	ADP
admet-348	58	10	two	two	NUM
admet-348	58	11	signaling	signal	VERB
admet-348	58	12	pathways	pathway	NOUN
admet-348	58	13	.	.	PUNCT
admet-348	59	1	in	in	ADP
admet-348	59	2	the	the	DET
admet-348	59	3	forthcoming	forthcoming	ADJ
admet-348	59	4	issue	issue	NOUN
admet-348	59	5	interaction	interaction	NOUN
admet-348	59	6	between	between	ADP
admet-348	59	7	the	the	DET
admet-348	59	8	cytotoxic	cytotoxic	ADJ
admet-348	59	9	drug	drug	NOUN
admet-348	59	10	gemcitabine	gemcitabine	NOUN
admet-348	59	11	and	and	CCONJ
admet-348	59	12	the	the	DET
admet-348	59	13	c	c	NOUN
admet-348	59	14	-	-	PUNCT
admet-348	59	15	met	meet	VERB
admet-348	59	16	inhibitor	inhibitor	NOUN
admet-348	59	17	crizotinib	crizotinib	NOUN
admet-348	59	18	will	will	AUX
admet-348	59	19	be	be	AUX
admet-348	59	20	described	describe	VERB
admet-348	59	21	,	,	PUNCT
admet-348	59	22	as	as	ADV
admet-348	59	23	well	well	ADV
admet-348	59	24	as	as	ADP
admet-348	59	25	the	the	DET
admet-348	59	26	development	development	NOUN
admet-348	59	27	of	of	ADP
admet-348	59	28	a	a	DET
admet-348	59	29	new	new	ADJ
admet-348	59	30	formulation	formulation	NOUN
admet-348	59	31	for	for	ADP
admet-348	59	32	a	a	DET
admet-348	59	33	novel	novel	ADJ
admet-348	59	34	polo	polo	NOUN
admet-348	59	35	-	-	PUNCT
admet-348	59	36	like	like	ADJ
admet-348	59	37	inhibitor	inhibitor	NOUN
admet-348	59	38	,	,	PUNCT
admet-348	59	39	which	which	PRON
admet-348	59	40	had	have	VERB
admet-348	59	41	to	to	PART
admet-348	59	42	take	take	VERB
admet-348	59	43	into	into	ADP
admet-348	59	44	account	account	NOUN
admet-348	59	45	all	all	DET
admet-348	59	46	above	above	ADV
admet-348	59	47	-	-	PUNCT
admet-348	59	48	described	describe	VERB
admet-348	59	49	problems	problem	NOUN
admet-348	59	50	,	,	PUNCT
admet-348	59	51	such	such	ADJ
admet-348	59	52	as	as	ADP
admet-348	59	53	poor	poor	ADJ
admet-348	59	54	solubility	solubility	NOUN
admet-348	59	55	,	,	PUNCT
admet-348	59	56	low	low	ADJ
admet-348	59	57	permeability	permeability	NOUN
admet-348	59	58	and	and	CCONJ
admet-348	59	59	the	the	DET
admet-348	59	60	crystalline	crystalline	ADJ
admet-348	59	61	nature	nature	NOUN
admet-348	59	62	.	.	PUNCT
admet-348	60	1	next	next	ADJ
admet-348	60	2	another	another	DET
admet-348	60	3	paper	paper	NOUN
admet-348	60	4	will	will	AUX
admet-348	60	5	focus	focus	VERB
admet-348	60	6	on	on	ADP
admet-348	60	7	an	an	DET
admet-348	60	8	alternate	alternate	ADJ
admet-348	60	9	target	target	NOUN
admet-348	60	10	for	for	ADP
admet-348	60	11	rock	rock	NOUN
admet-348	60	12	inhibitors	inhibitor	NOUN
admet-348	60	13	,	,	PUNCT
admet-348	60	14	ocular	ocular	ADJ
admet-348	60	15	disease	disease	NOUN
admet-348	60	16	.	.	PUNCT
admet-348	61	1	earlier	early	ADV
admet-348	61	2	the	the	DET
admet-348	61	3	anti	anti	ADJ
admet-348	61	4	-	-	ADJ
admet-348	61	5	angiogenic	angiogenic	ADJ
admet-348	61	6	antibody	antibody	NOUN
admet-348	61	7	bevacizumab	bevacizumab	NOUN
admet-348	61	8	was	be	AUX
admet-348	61	9	already	already	ADV
admet-348	61	10	indicated	indicate	VERB
admet-348	61	11	for	for	ADP
admet-348	61	12	ocular	ocular	ADJ
admet-348	61	13	diseases	disease	NOUN
admet-348	61	14	as	as	ADV
admet-348	61	15	well	well	ADV
admet-348	61	16	.	.	PUNCT
admet-348	62	1	other	other	ADJ
admet-348	62	2	aspects	aspect	NOUN
admet-348	62	3	which	which	PRON
admet-348	62	4	will	will	AUX
admet-348	62	5	receive	receive	VERB
admet-348	62	6	attention	attention	NOUN
admet-348	62	7	are	be	AUX
admet-348	62	8	the	the	DET
admet-348	62	9	role	role	NOUN
admet-348	62	10	of	of	ADP
admet-348	62	11	various	various	ADJ
admet-348	62	12	efflux	efflux	NOUN
admet-348	62	13	pumps	pump	NOUN
admet-348	62	14	for	for	ADP
admet-348	62	15	various	various	ADJ
admet-348	62	16	tyrosine	tyrosine	NOUN
admet-348	62	17	kinases	kinase	NOUN
admet-348	62	18	and	and	CCONJ
admet-348	62	19	how	how	SCONJ
admet-348	62	20	to	to	PART
admet-348	62	21	use	use	VERB
admet-348	62	22	docking	docking	NOUN
admet-348	62	23	models	model	NOUN
admet-348	62	24	to	to	PART
admet-348	62	25	develop	develop	VERB
admet-348	62	26	kinase	kinase	ADJ
admet-348	62	27	inhibitors	inhibitor	NOUN
admet-348	62	28	.	.	PUNCT
admet-348	63	1	with	with	ADP
admet-348	63	2	this	this	DET
admet-348	63	3	selection	selection	NOUN
admet-348	63	4	of	of	ADP
admet-348	63	5	papers	paper	NOUN
admet-348	63	6	we	we	PRON
admet-348	63	7	want	want	VERB
admet-348	63	8	to	to	PART
admet-348	63	9	emphasize	emphasize	VERB
admet-348	63	10	that	that	SCONJ
admet-348	63	11	with	with	ADP
admet-348	63	12	proper	proper	ADJ
admet-348	63	13	attention	attention	NOUN
admet-348	63	14	to	to	ADP
admet-348	63	15	the	the	DET
admet-348	63	16	role	role	NOUN
admet-348	63	17	of	of	ADP
admet-348	63	18	admet	admet	NOUN
admet-348	63	19	the	the	DET
admet-348	63	20	use	use	NOUN
admet-348	63	21	of	of	ADP
admet-348	63	22	the	the	DET
admet-348	63	23	protein	protein	NOUN
admet-348	63	24	kinase	kinase	NOUN
admet-348	63	25	inhibitors	inhibitor	NOUN
admet-348	63	26	can	can	AUX
admet-348	63	27	be	be	AUX
admet-348	63	28	improved	improve	VERB
admet-348	63	29	and	and	CCONJ
admet-348	63	30	extended	extend	VERB
admet-348	63	31	to	to	ADP
admet-348	63	32	other	other	ADJ
admet-348	63	33	applications	application	NOUN
admet-348	63	34	,	,	PUNCT
admet-348	63	35	while	while	SCONJ
admet-348	63	36	for	for	SCONJ
admet-348	63	37	some	some	DET
admet-348	63	38	drugs	drug	NOUN
admet-348	63	39	development	development	NOUN
admet-348	63	40	should	should	AUX
admet-348	63	41	have	have	AUX
admet-348	63	42	been	be	AUX
admet-348	63	43	discontinued	discontinue	VERB
admet-348	63	44	earlier	early	ADV
admet-348	63	45	.	.	PUNCT
admet-348	64	1	it	it	PRON
admet-348	64	2	can	can	AUX
admet-348	64	3	also	also	ADV
admet-348	64	4	be	be	AUX
admet-348	64	5	concluded	conclude	VERB
admet-348	64	6	that	that	SCONJ
admet-348	64	7	dose	dose	NOUN
admet-348	64	8	adaptation	adaptation	NOUN
admet-348	64	9	is	be	AUX
admet-348	64	10	sometimes	sometimes	ADV
admet-348	64	11	necessary	necessary	ADJ
admet-348	64	12	due	due	ADP
admet-348	64	13	to	to	ADP
admet-348	64	14	poor	poor	ADJ
admet-348	64	15	admet	admet	NOUN
admet-348	64	16	properties	property	NOUN
admet-348	64	17	.	.	PUNCT
admet-348	65	1	references	reference	NOUN
admet-348	65	2	[	[	X
admet-348	65	3	1	1	NUM
admet-348	65	4	]	]	X
admet-348	65	5	f.	f.	PROPN
admet-348	65	6	broekman	broekman	PROPN
admet-348	65	7	,	,	PUNCT
admet-348	65	8	e.	e.	PROPN
admet-348	65	9	giovannetti	giovannetti	PROPN
admet-348	65	10	,	,	PUNCT
admet-348	65	11	g.j	g.j	PROPN
admet-348	65	12	.	.	PROPN
admet-348	65	13	peters	peters	PROPN
admet-348	65	14	.	.	PUNCT
admet-348	66	1	world	world	PROPN
admet-348	66	2	j.	j.	PROPN
admet-348	66	3	clin	clin	PROPN
admet-348	66	4	.	.	PUNCT
admet-348	67	1	oncol	oncol	ADJ
admet-348	67	2	.	.	PUNCT
admet-348	68	1	2	2	NUM
admet-348	68	2	,	,	PUNCT
admet-348	68	3	(	(	PUNCT
admet-348	68	4	2011	2011	NUM
admet-348	68	5	)	)	PUNCT
admet-348	68	6	80	80	NUM
admet-348	68	7	-	-	SYM
admet-348	68	8	93	93	NUM
admet-348	68	9	.	.	PUNCT
admet-348	69	1	[	[	X
admet-348	69	2	2	2	NUM
admet-348	69	3	]	]	PUNCT
admet-348	69	4	p.	p.	PROPN
admet-348	69	5	wu	wu	PROPN
admet-348	69	6	,	,	PUNCT
admet-348	69	7	t.e	t.e	PROPN
admet-348	69	8	.	.	PROPN
admet-348	69	9	nielsen	nielsen	PROPN
admet-348	69	10	,	,	PUNCT
admet-348	69	11	m.h	m.h	PROPN
admet-348	69	12	.	.	PROPN
admet-348	69	13	clausen	clausen	PROPN
admet-348	69	14	.	.	PUNCT
admet-348	70	1	trends	trend	NOUN
admet-348	70	2	in	in	ADP
admet-348	70	3	pharmacological	pharmacological	ADJ
admet-348	70	4	sciences	science	NOUN
admet-348	70	5	36	36	NUM
admet-348	70	6	(	(	PUNCT
admet-348	70	7	2015	2015	NUM
admet-348	70	8	)	)	PUNCT
admet-348	70	9	422	422	NUM
admet-348	70	10	-	-	SYM
admet-348	70	11	439	439	NUM
admet-348	70	12	.	.	PUNCT
admet-348	71	1	[	[	X
admet-348	71	2	3	3	NUM
admet-348	71	3	]	]	X
admet-348	71	4	c.g	c.g	PROPN
admet-348	71	5	.	.	PROPN
admet-348	71	6	da	da	PROPN
admet-348	71	7	silva	silva	PROPN
admet-348	71	8	,	,	PUNCT
admet-348	71	9	r.j	r.j	PROPN
admet-348	71	10	.	.	PROPN
admet-348	71	11	honeywell	honeywell	PROPN
admet-348	71	12	,	,	PUNCT
admet-348	71	13	h.	h.	PROPN
admet-348	71	14	dekker	dekker	PROPN
admet-348	71	15	,	,	PUNCT
admet-348	71	16	g.j	g.j	PROPN
admet-348	71	17	.	.	PROPN
admet-348	71	18	peters	peters	PROPN
admet-348	71	19	.	.	PUNCT
admet-348	72	1	expert	expert	ADJ
admet-348	72	2	opinion	opinion	NOUN
admet-348	72	3	drug	drug	NOUN
admet-348	72	4	metab	metab	NOUN
admet-348	72	5	.	.	PUNCT
admet-348	73	1	toxicol	toxicol	PROPN
admet-348	73	2	.	.	PUNCT
admet-348	74	1	11	11	NUM
admet-348	74	2	(	(	PUNCT
admet-348	74	3	2015	2015	NUM
admet-348	74	4	)	)	PUNCT
admet-348	74	5	703	703	NUM
admet-348	74	6	-	-	SYM
admet-348	74	7	717	717	NUM
admet-348	74	8	.	.	PUNCT
admet-348	75	1	[	[	X
admet-348	75	2	4	4	NUM
admet-348	75	3	]	]	X
admet-348	75	4	r.j	r.j	PROPN
admet-348	75	5	.	.	PROPN
admet-348	75	6	honeywell	honeywell	PROPN
admet-348	75	7	,	,	PUNCT
admet-348	75	8	c.	c.	PROPN
admet-348	75	9	fatmawati	fatmawati	PROPN
admet-348	75	10	,	,	PUNCT
admet-348	75	11	m.	m.	NOUN
admet-348	75	12	buddha	buddha	PROPN
admet-348	75	13	,	,	PUNCT
admet-348	75	14	s.	s.	PROPN
admet-348	75	15	hitzerd	hitzerd	PROPN
admet-348	75	16	,	,	PUNCT
admet-348	75	17	i.	i.	PROPN
admet-348	75	18	kathman	kathman	PROPN
admet-348	75	19	,	,	PUNCT
admet-348	75	20	g.j	g.j	PROPN
admet-348	75	21	.	.	PROPN
admet-348	75	22	peters	peters	PROPN
admet-348	75	23	.	.	PUNCT
admet-348	76	1	admet	admet	PROPN
admet-348	76	2	&	&	CCONJ
admet-348	76	3	dmpk	dmpk	PROPN
admet-348	76	4	3	3	NUM
admet-348	76	5	(	(	PUNCT
admet-348	76	6	2015	2015	NUM
admet-348	76	7	)	)	PUNCT
admet-348	76	8	51	51	NUM
admet-348	76	9	-	-	SYM
admet-348	76	10	67	67	NUM
admet-348	76	11	.	.	PUNCT
admet-348	77	1	[	[	X
admet-348	77	2	5	5	NUM
admet-348	77	3	]	]	PUNCT
admet-348	77	4	a.	a.	NOUN
admet-348	77	5	sparreboom	sparreboom	NOUN
admet-348	77	6	,	,	PUNCT
admet-348	77	7	j.	j.	PROPN
admet-348	77	8	verweij	verweij	PROPN
admet-348	77	9	.	.	PUNCT
admet-348	78	1	clin	clin	PROPN
admet-348	78	2	pharmacol	pharmacol	PROPN
admet-348	78	3	.	.	PUNCT
admet-348	79	1	ther	ther	PROPN
admet-348	79	2	85	85	NUM
admet-348	79	3	(	(	PUNCT
admet-348	79	4	2009	2009	NUM
admet-348	79	5	)	)	PUNCT
admet-348	79	6	113	113	NUM
admet-348	79	7	-	-	SYM
admet-348	79	8	117	117	NUM
admet-348	79	9	[	[	SYM
admet-348	79	10	6	6	NUM
admet-348	79	11	]	]	X
admet-348	79	12	m.j	m.j	PROPN
admet-348	79	13	.	.	PROPN
admet-348	79	14	ratain	ratain	PROPN
admet-348	79	15	.	.	PUNCT
admet-348	80	1	j	j	PROPN
admet-348	80	2	clin	clin	PROPN
admet-348	80	3	oncol	oncol	PROPN
admet-348	80	4	.	.	PUNCT
admet-348	81	1	29	29	NUM
admet-348	81	2	(	(	PUNCT
admet-348	81	3	2011	2011	NUM
admet-348	81	4	)	)	PUNCT
admet-348	81	5	3958	3958	NUM
admet-348	81	6	-	-	SYM
admet-348	81	7	9	9	NUM
admet-348	81	8	.	.	PUNCT
admet-348	82	1	[	[	X
admet-348	82	2	7	7	X
admet-348	82	3	]	]	X
admet-348	82	4	n.	n.	PROPN
admet-348	82	5	van	van	PROPN
admet-348	82	6	der	der	PROPN
admet-348	82	7	steen	steen	PROPN
admet-348	82	8	,	,	PUNCT
admet-348	82	9	c.	c.	PROPN
admet-348	82	10	caparello	caparello	PROPN
admet-348	82	11	,	,	PUNCT
admet-348	82	12	c.	c.	PROPN
admet-348	82	13	rolfo	rolfo	PROPN
admet-348	82	14	,	,	PUNCT
admet-348	82	15	p.	p.	NOUN
admet-348	82	16	pauwels	pauwel	NOUN
admet-348	82	17	,	,	PUNCT
admet-348	82	18	g.j	g.j	PROPN
admet-348	82	19	.	.	PROPN
admet-348	82	20	peters	peters	PROPN
admet-348	82	21	,	,	PUNCT
admet-348	82	22	e.	e.	PROPN
admet-348	82	23	giovannetti	giovannetti	PROPN
admet-348	82	24	.	.	PUNCT
admet-348	83	1	oncotarget	oncotarget	PROPN
admet-348	83	2	&	&	CCONJ
admet-348	83	3	therapy	therapy	NOUN
admet-348	83	4	(	(	PUNCT
admet-348	83	5	2016	2016	NUM
admet-348	83	6	)	)	PUNCT
admet-348	83	7	in	in	ADP
admet-348	83	8	press	press	NOUN
admet-348	83	9	.	.	PUNCT
admet-348	84	1	[	[	X
admet-348	84	2	8	8	NUM
admet-348	84	3	]	]	X
admet-348	84	4	i.b	i.b	PROPN
admet-348	84	5	.	.	PROPN
admet-348	84	6	muller	muller	PROPN
admet-348	84	7	,	,	PUNCT
admet-348	84	8	a.j	a.j	PROPN
admet-348	84	9	.	.	PROPN
admet-348	84	10	de	de	PROPN
admet-348	84	11	langen	langen	PROPN
admet-348	84	12	,	,	PUNCT
admet-348	84	13	r.j	r.j	PROPN
admet-348	84	14	.	.	PROPN
admet-348	84	15	honeywell	honeywell	PROPN
admet-348	84	16	,	,	PUNCT
admet-348	84	17	e.	e.	PROPN
admet-348	84	18	giovannetti	giovannetti	PROPN
admet-348	84	19	,	,	PUNCT
admet-348	84	20	g.j	g.j	PROPN
admet-348	84	21	.	.	PROPN
admet-348	84	22	peters	peters	PROPN
admet-348	84	23	.	.	PUNCT
admet-348	85	1	exp	exp	NOUN
admet-348	85	2	review	review	NOUN
admet-348	85	3	anticancer	anticancer	NOUN
admet-348	85	4	therapy	therapy	NOUN
admet-348	85	5	16	16	NUM
admet-348	85	6	(	(	PUNCT
admet-348	85	7	2016	2016	NUM
admet-348	85	8	)	)	PUNCT
admet-348	85	9	147	147	NUM
admet-348	85	10	-	-	SYM
admet-348	85	11	157	157	NUM
admet-348	85	12	.	.	PUNCT
admet-348	86	1	admet	admet	PROPN
admet-348	86	2	&	&	CCONJ
admet-348	86	3	dmpk	dmpk	PROPN
admet-348	86	4	4(3	4(3	NUM
admet-348	86	5	)	)	PUNCT
admet-348	86	6	(	(	PUNCT
admet-348	86	7	2016	2016	NUM
admet-348	86	8	)	)	PUNCT
admet-348	86	9	182	182	NUM
admet-348	86	10	-	-	SYM
admet-348	86	11	185	185	NUM
admet-348	86	12	tki	tki	NOUN
admet-348	86	13	special	special	ADJ
admet-348	86	14	issue	issue	NOUN
admet-348	86	15	editorial	editorial	ADJ
admet-348	86	16	doi	doi	NOUN
admet-348	86	17	:	:	PUNCT
admet-348	86	18	10.5599	10.5599	NUM
admet-348	86	19	/	/	SYM
admet-348	86	20	admet.4.3.348	admet.4.3.348	PROPN
admet-348	86	21	185	185	NUM
admet-348	86	22	[	[	SYM
admet-348	86	23	9	9	NUM
admet-348	86	24	]	]	X
admet-348	86	25	c.	c.	PROPN
admet-348	86	26	delbaldo	delbaldo	PROPN
admet-348	86	27	,	,	PUNCT
admet-348	86	28	e.	e.	PROPN
admet-348	86	29	chatelut	chatelut	PROPN
admet-348	86	30	,	,	PUNCT
admet-348	86	31	m.	m.	NOUN
admet-348	86	32	ré	ré	PROPN
admet-348	86	33	,	,	PUNCT
admet-348	86	34	a.	a.	NOUN
admet-348	86	35	deroussent	deroussent	NOUN
admet-348	86	36	,	,	PUNCT
admet-348	86	37	s.	s.	PROPN
admet-348	86	38	séronie	séronie	PROPN
admet-348	86	39	-	-	PUNCT
admet-348	86	40	vivien	vivien	PROPN
admet-348	86	41	,	,	PUNCT
admet-348	86	42	a.	a.	NOUN
admet-348	86	43	jambu	jambu	PROPN
admet-348	86	44	,	,	PUNCT
admet-348	86	45	p.	p.	NOUN
admet-348	86	46	berthaud	berthaud	PROPN
admet-348	86	47	,	,	PUNCT
admet-348	86	48	a.	a.	NOUN
admet-348	86	49	le	le	X
admet-348	86	50	cesne	cesne	PROPN
admet-348	86	51	,	,	PUNCT
admet-348	86	52	j.y	j.y	PROPN
admet-348	86	53	.	.	PROPN
admet-348	86	54	blay	blay	PROPN
admet-348	86	55	,	,	PUNCT
admet-348	86	56	g.	g.	PROPN
admet-348	86	57	vassal	vassal	NOUN
admet-348	86	58	.	.	PUNCT
admet-348	87	1	clin	clin	PROPN
admet-348	87	2	cancer	cancer	NOUN
admet-348	87	3	res	re	NOUN
admet-348	87	4	.	.	PUNCT
admet-348	88	1	12(20	12(20	NUM
admet-348	88	2	pt	pt	NOUN
admet-348	88	3	1	1	NUM
admet-348	88	4	)	)	PUNCT
admet-348	88	5	(	(	PUNCT
admet-348	88	6	2006	2006	NUM
admet-348	88	7	)	)	PUNCT
admet-348	88	8	6073	6073	NUM
admet-348	88	9	-	-	SYM
admet-348	88	10	8	8	NUM
admet-348	88	11	.	.	PUNCT
admet-348	89	1	[	[	X
admet-348	89	2	10	10	NUM
admet-348	89	3	]	]	X
admet-348	89	4	s.d	s.d	PROPN
admet-348	89	5	.	.	PROPN
admet-348	89	6	baker	baker	PROPN
admet-348	89	7	,	,	PUNCT
admet-348	89	8	s.	s.	PROPN
admet-348	89	9	hu	hu	PROPN
admet-348	89	10	.	.	PROPN
admet-348	89	11	clin	clin	PROPN
admet-348	89	12	pharmacol	pharmacol	PROPN
admet-348	89	13	ther	ther	ADV
admet-348	89	14	85	85	NUM
admet-348	89	15	(	(	PUNCT
admet-348	89	16	2009	2009	NUM
admet-348	89	17	)	)	PUNCT
admet-348	89	18	208	208	NUM
admet-348	89	19	-	-	SYM
admet-348	89	20	211	211	NUM
admet-348	89	21	.	.	PUNCT
admet-348	90	1	[	[	X
admet-348	90	2	11	11	NUM
admet-348	90	3	]	]	X
admet-348	90	4	e.i	e.i	PROPN
admet-348	90	5	.	.	PROPN
admet-348	90	6	zimmerman	zimmerman	PROPN
admet-348	90	7	,	,	PUNCT
admet-348	90	8	s.	s.	PROPN
admet-348	90	9	hu	hu	PROPN
admet-348	90	10	,	,	PUNCT
admet-348	90	11	j.l	j.l	PROPN
admet-348	90	12	.	.	PROPN
admet-348	90	13	roberts	roberts	PROPN
admet-348	90	14	,	,	PUNCT
admet-348	90	15	a.a	a.a	PROPN
admet-348	90	16	.	.	PROPN
admet-348	90	17	gibson	gibson	PROPN
admet-348	90	18	,	,	PUNCT
admet-348	90	19	s.j	s.j	PROPN
admet-348	90	20	.	.	PROPN
admet-348	90	21	orwick	orwick	PROPN
admet-348	90	22	,	,	PUNCT
admet-348	90	23	l.	l.	PROPN
admet-348	90	24	li	li	PROPN
admet-348	90	25	,	,	PUNCT
admet-348	90	26	a.	a.	NOUN
admet-348	90	27	sparreboom	sparreboom	PROPN
admet-348	90	28	,	,	PUNCT
admet-348	90	29	s.d	s.d	PROPN
admet-348	90	30	.	.	PROPN
admet-348	90	31	baker	baker	PROPN
admet-348	90	32	.	.	PUNCT
admet-348	91	1	clin	clin	PROPN
admet-348	91	2	cancer	cancer	NOUN
admet-348	91	3	res	re	NOUN
admet-348	91	4	.	.	PROPN
admet-348	92	1	19	19	NUM
admet-348	92	2	(	(	PUNCT
admet-348	92	3	2013	2013	NUM
admet-348	92	4	)	)	PUNCT
admet-348	92	5	1458	1458	NUM
admet-348	92	6	-	-	SYM
admet-348	92	7	66	66	NUM
admet-348	92	8	.	.	PUNCT
admet-348	93	1	[	[	X
admet-348	93	2	12	12	NUM
admet-348	93	3	]	]	X
admet-348	93	4	j.r	j.r	PROPN
admet-348	93	5	.	.	PROPN
admet-348	93	6	thompson	thompson	PROPN
admet-348	93	7	,	,	PUNCT
admet-348	93	8	s.p	s.p	PROPN
admet-348	93	9	.	.	PROPN
admet-348	93	10	menon	menon	PROPN
admet-348	93	11	,	,	PUNCT
admet-348	93	12	g.k	g.k	PROPN
admet-348	93	13	.	.	PROPN
admet-348	93	14	dy	dy	PROPN
admet-348	93	15	.	.	PROPN
admet-348	93	16	admet	admet	PROPN
admet-348	93	17	&	&	CCONJ
admet-348	93	18	dmpk	dmpk	PROPN
admet-348	93	19	4	4	NUM
admet-348	93	20	(	(	PUNCT
admet-348	93	21	2016	2016	NUM
admet-348	93	22	)	)	PUNCT
admet-348	93	23	186	186	NUM
admet-348	93	24	-	-	SYM
admet-348	93	25	211	211	NUM
admet-348	93	26	.	.	PUNCT
admet-348	94	1	[	[	X
admet-348	94	2	13	13	NUM
admet-348	94	3	]	]	PUNCT
admet-348	94	4	r.	r.	PROPN
admet-348	94	5	shah	shah	PROPN
admet-348	94	6	.	.	PUNCT
admet-348	95	1	admet	admet	PROPN
admet-348	95	2	&	&	CCONJ
admet-348	95	3	dmpk	dmpk	PROPN
admet-348	95	4	4	4	NUM
admet-348	95	5	(	(	PUNCT
admet-348	95	6	2016	2016	NUM
admet-348	95	7	)	)	PUNCT
admet-348	95	8	212	212	NUM
admet-348	95	9	-	-	SYM
admet-348	95	10	231	231	NUM
admet-348	95	11	.	.	PUNCT
admet-348	96	1	[	[	X
admet-348	96	2	14	14	NUM
admet-348	96	3	]	]	X
admet-348	96	4	g.b	g.b	PROPN
admet-348	96	5	.	.	PROPN
admet-348	96	6	pott	pott	PROPN
admet-348	96	7	,	,	PUNCT
admet-348	96	8	m.	m.	NOUN
admet-348	96	9	tsurudome	tsurudome	PROPN
admet-348	96	10	,	,	PUNCT
admet-348	96	11	j.	j.	PROPN
admet-348	96	12	bui	bui	PROPN
admet-348	96	13	,	,	PUNCT
admet-348	96	14	c.	c.	PROPN
admet-348	96	15	gardner	gardner	PROPN
admet-348	96	16	,	,	PUNCT
admet-348	96	17	m.l	m.l	PROPN
admet-348	96	18	.	.	PROPN
admet-348	96	19	goalstone	goalstone	NOUN
admet-348	96	20	.	.	PUNCT
admet-348	97	1	admet	admet	PROPN
admet-348	97	2	&	&	CCONJ
admet-348	97	3	dmpk	dmpk	PROPN
admet-348	97	4	4	4	NUM
admet-348	97	5	(	(	PUNCT
admet-348	97	6	2016	2016	NUM
admet-348	97	7	)	)	PUNCT
admet-348	97	8	232	232	NUM
admet-348	97	9	-	-	SYM
admet-348	97	10	240	240	NUM
admet-348	97	11	.	.	PUNCT
admet-348	98	1	©	©	PROPN
admet-348	98	2	2016	2016	NUM
admet-348	98	3	by	by	ADP
admet-348	98	4	the	the	DET
admet-348	98	5	authors	author	NOUN
admet-348	98	6	;	;	PUNCT
admet-348	99	1	licensee	licensee	PROPN
admet-348	99	2	iapc	iapc	PROPN
admet-348	99	3	,	,	PUNCT
admet-348	99	4	zagreb	zagreb	PROPN
admet-348	99	5	,	,	PUNCT
admet-348	99	6	croatia	croatia	PROPN
admet-348	99	7	.	.	PUNCT
admet-348	100	1	this	this	DET
admet-348	100	2	article	article	NOUN
admet-348	100	3	is	be	AUX
admet-348	100	4	an	an	DET
admet-348	100	5	open	open	ADJ
admet-348	100	6	-	-	PUNCT
admet-348	100	7	access	access	NOUN
admet-348	100	8	article	article	NOUN
admet-348	100	9	distributed	distribute	VERB
admet-348	100	10	under	under	ADP
admet-348	100	11	the	the	DET
admet-348	100	12	terms	term	NOUN
admet-348	100	13	and	and	CCONJ
admet-348	100	14	conditions	condition	NOUN
admet-348	100	15	of	of	ADP
admet-348	100	16	the	the	DET
admet-348	100	17	creative	creative	ADJ
admet-348	100	18	commons	common	NOUN
admet-348	100	19	attribution	attribution	NOUN
admet-348	100	20	license	license	NOUN
admet-348	100	21	(	(	PUNCT
admet-348	100	22	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN
admet-348	100	23	)	)	PUNCT
admet-348	100	24	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN